Peptide evidence review

What the research actually shows about BPC-157

BPC-157 has a large and reproducible animal-research record for healing tendon, ligament, muscle, gut, and skin injuries, and almost none of it has been tested in people. The only published human study is a single small, uncontrolled case series of knee injections; there has never been a human randomized trial. It is not approved by the FDA, which has placed it on a list of compounding substances that may present significant safety risks, and it is banned in sport at all times.

The honest read

BPC-157 has a large, reproducible animal-research record for healing injured tendon, ligament, muscle, gut, and skin, and almost none of it has been tested in people. That is the whole tension of this compound. The laboratory and animal story is genuinely interesting and unusually consistent. The human story is a single small, uncontrolled case series of knee injections. There has never been a published human randomized controlled trial of BPC-157 for anything.

The rest of the honest read is the part the marketing skips. BPC-157 is not approved by the FDA, which has placed it on a list of bulk substances for compounding that may present significant safety risks, citing immunogenicity and peptide-impurity concerns, so it is not eligible for pharmacy compounding. There is no published human safety dataset at all. Most of the promising preclinical work comes from a small number of research groups, which is exactly the situation where independent replication matters most. And it is banned in sport at all times; it was, in fact, the first substance ever named by example in the World Anti-Doping Agency's non-approved-substances category.

This piece grades each claim by the strength of the evidence behind it, separates carefully what was shown in animals from what was shown in people, and surfaces the safety and regulatory status you would want before any conversation with a clinician.

What BPC-157 is and how it is thought to work

BPC-157 is a synthetic peptide of fifteen amino acids. It is marketed as a partial sequence of a larger protein, "Body Protection Compound," reported to occur in gastric juice, and it carries research designations such as PL-14736 from its earlier pharmaceutical development. It is not a hormone and not a growth-hormone secretagogue, which sets it apart from compounds like ipamorelin and CJC-1295; its proposed role is tissue protection and repair rather than hormone signaling.

The mechanisms attributed to it are interesting, and they share one feature you should keep in mind: every one of them has been demonstrated in animals or in isolated cells, not in living human tissue. In isolated rat blood vessels, BPC-157 produced nitric-oxide-dependent relaxation and promoted endothelial-cell migration through a signaling pathway involving eNOS (Hsieh et al. 2020). In tendon explants and cultured tendon cells, it accelerated cell outgrowth and migration through the FAK and paxillin pathway, without directly increasing cell proliferation (Chang et al. 2011). In healing wounds it has been linked to early growth-response signaling that organizes collagen (Tkalčević et al. 2007). The research group most associated with the compound frames all of this as a single cytoprotective system acting on the nitric-oxide pathway, blood-vessel function, and new-vessel formation (Sikirić et al. 2018).

Two honest caveats travel with that mechanistic story. The first is the model: a pathway shown in a rat aorta or a dish of tendon cells is a reason to investigate, not a demonstrated effect in a person. The second is concentration of evidence: much of the unifying mechanism originates substantially from one research group, and no validated human-tissue mechanism has been established. Interesting is the right word for the mechanism. Proven is not.

What the research actually shows, graded by evidence tier

Here is the split that matters most, stated plainly. The empirical research on BPC-157 is roughly one human study, eleven animal studies, and a handful of cell and tissue studies. The human study is a single uncontrolled case series. A search of the published literature for a randomized controlled trial or a formal clinical trial of BPC-157 returns nothing. So the picture is unusual: a deep, broadly positive animal record, and an almost empty human one.

The preclinical signal is real and worth taking seriously as a reason to study the compound. It is also, so far, preclinical. The sections below walk each use case at its own tier.

That asymmetry is the single most useful thing to hold onto. With most compounds the question is whether the human evidence is strong or weak. With BPC-157 the question comes earlier: there is essentially no human efficacy evidence to grade, and no published human safety evidence at all, so every decision is being made on animal data plus hope. Naming that honestly is the point of this page.

Soft-tissue healing: the preclinical core, all in animals

The strongest part of the BPC-157 story is soft-tissue repair, and it is in rats. In rat studies, BPC-157 accelerated the healing of a transected Achilles tendon with improved mechanical function (Staresinic et al. 2003), promoted tendon-to-bone healing after tendon detachment and offset the damage corticosteroids do to that healing (Krivić et al. 2006), improved medial collateral ligament healing over ninety days (Cerovečki et al. 2010), and improved the healing of a cut quadriceps muscle (Staresinic et al. 2006). The supporting cell-level work, on tendon-cell migration and survival, is consistent with these findings (Chang et al. 2011).

This is a genuinely reproducible body of animal evidence, and it is the reason BPC-157 is taken seriously enough to study. It is also entirely animal. Independent reviews that have surveyed this literature reach the same two-part conclusion: the preclinical healing results are consistent, and the efficacy "is yet to be confirmed in humans," with only a handful of research groups having studied it (Gwyer et al. 2019; DeFoor and Dekker 2025).

It is worth saying why animal results, however consistent, cannot stand in for a human one. A rat tendon mended in a controlled cage study is not a middle-aged human tendon under daily load, with different biology, different timelines, and different ways things go wrong. Animal efficacy is the reason to run a human trial, not a substitute for one, and for BPC-157 that human trial has not happened.

Gut and inflammatory bowel disease: the original target, animal models and an unverifiable trial claim

BPC-157's earliest development target was the gut. In a wide range of rat models it has shown anti-ulcer and protective effects, including healing of difficult gastrointestinal injuries and fistulas (Sikirić et al. 2006; Skorjanec et al. 2009; Ilić et al. 2011), and reviews focused on ulcerative colitis describe the same protective pattern (Sikirić et al. 2012). One caution is essential here. Review articles sometimes refer to historical "Phase II" human trials of a BPC-157-related compound for inflammatory bowel disease, but no corresponding primary, peer-reviewed publication is findable in the medical literature. Those references cannot be independently verified, and they should not be treated as published human evidence. As it stands, the gut evidence is animal.

Skin wounds and brain injury: animal only

The same pattern holds across other tissues. BPC-157 accelerated skin-wound healing in diabetic rats and improved the quality of healing tissue (Seveljević-Jaran et al. 2006; Tkalčević et al. 2007), and it showed benefit in animal models of traumatic brain injury and in rat studies of central nervous-system signaling (Tudor et al. 2010; Zemba Cilic et al. 2021). These are real findings in mice and rats. None has been tested in people.

A note on who produced the evidence

One feature of the BPC-157 literature deserves to be named, because it bears on how much weight the animal results can carry. A large share of the positive preclinical work, and almost all of the unifying mechanistic theory, comes from a small number of research groups, principally one university group that has studied the compound for decades. That is not an accusation; pioneering groups often lead a field. But independent replication by unaffiliated labs is how a promising animal finding earns confidence, and for BPC-157 that broad independent replication is still thin. Reviewers from outside the originating groups make the same point: the results are interesting, and the field studying them is narrow (Gwyer et al. 2019; Mayfield et al. 2026).

The one human study: a small, uncontrolled knee-pain case series

The entire published human efficacy record for BPC-157 is a single retrospective case series from one private clinic, in which a small number of patients who had received BPC-157 injections for various kinds of knee pain were later phoned and asked to recall how much they had improved (Lee and Padgett 2021). Most reported subjective improvement. That is the high-water mark of human evidence for this molecule, and it has to be read for exactly what it is: a tiny, uncontrolled, recall-based survey with no comparison group and no validated outcome measures. An independent 2026 sports-medicine review judged it to have significant methodological flaws and a lack of controls that limit its reliability (Mayfield et al. 2026). It is hypothesis-generating, not proof of anything, and the specific response figures it reported should not be repeated as if they were a dependable success rate.

Safety and what we don't know

The honest framing on safety is uncomfortable and important: there is no published human safety dataset for BPC-157. A Phase 1 safety and pharmacokinetics study was registered, but its status is listed as unknown and no results were ever posted, so even basic human pharmacokinetics are effectively a blank in the public record. The absence of reported side effects is not evidence of safety; it is evidence that the rigorous human studies that would detect side effects were never done.

The authoritative current safety signal comes from the FDA. In placing BPC-157 on its list of bulk substances that may present significant safety risks, the agency stated that compounded BPC-157 may pose a risk of immunogenicity for certain routes of administration and may carry complexities around peptide-related impurities and active-ingredient characterization, and that it had identified little safety information for the proposed routes (U.S. Food and Drug Administration 503A list). That is a regulator looking at the same evidence and concluding the risks are unresolved. The benign-safety-profile language you will see in some reviews comes substantially from the originating research group and describes animals, not people.

Because no regulated label exists, there are no established human contraindications or drug-interaction data. Animal work shows BPC-157 interacts pharmacodynamically with the nitric-oxide system, which is mechanistically interesting but not a validated human interaction. There is one more hazard that is independent of the molecule itself: BPC-157 is sold almost entirely as an unregulated "research chemical," so what is actually in a given vial, its identity, purity, and dose, is not guaranteed, and mislabeled or contaminated material is a documented reality. There is no validated human dose, frequency, or duration; the regimens that appear in the literature are rodent experimental doses, and the most candid independent review states plainly that the indications, dosing, frequency, and duration of treatment remain unknown (Mayfield et al. 2026).

It is worth being plain about the legal status too, because it shapes the risk. BPC-157 is not an approved drug, not a lawful dietary supplement, and, under the FDA's compounding designation, not something a pharmacy may lawfully compound. What remains is an unregulated market that sells it as a research chemical labeled not for human consumption. That status is itself information: no manufacturer is accountable for what is actually in the vial, and no regulator has cleared it for the use buyers are putting it to.

FDA status and anti-doping (WADA) status

The regulatory picture is the part of the BPC-157 story the marketing tends to skip, so it leads here.

First, FDA status: BPC-157 is not approved by the FDA for any use, and it is not a lawful dietary supplement, because it is a synthetic drug substance rather than a dietary ingredient. Concretely, the FDA has placed BPC-157 on its 503A list of "certain bulk drug substances for use in compounding that may present significant safety risks," a designation, current as of the 2026 list update, that means it is not eligible for use in pharmacy compounding pending further evaluation (U.S. Food and Drug Administration 503A list; FDA interim 503A policy guidance). In plain terms, it is unapproved, it is not legally compoundable, and it is not a supplement; it is sold online as a research chemical labeled not for human consumption, and anti-doping authorities note there is no legal basis for its use in humans (U.S. Anti-Doping Agency).

Second, anti-doping status: BPC-157 is prohibited under Section S0, the non-approved-substances category, of the World Anti-Doping Agency Prohibited List, prohibited at all times, in and out of competition, effective since the first of January 2022 (World Anti-Doping Agency; U.S. Anti-Doping Agency). It holds a particular distinction: it was the first substance ever named by example in that category, described by WADA as an experimental peptide sold as a supplement. It is also detectable; anti-doping laboratories have developed validated methods to find BPC-157 and its breakdown products in human urine (Tian et al. 2023). Any athlete subject to anti-doping rules who uses it commits a violation, and this belongs prominently in front of anyone who competes.

How and when to think about using BPC-157

Vague "ask your doctor" is not useful, so here is the specific version, and for BPC-157 the specific version starts with an honest hard stop. There is no evidence-based dose, because there is no human trial. Every dose, route, and schedule you will see quoted comes from animal experiments or from what people and clinics report doing, not from anything tested for safety or efficacy in a person. We are not going to hand you a protocol the evidence does not support. What we can do is lay out how to think about the decision, and report, in the next section, what is actually done, so you are deciding with open eyes rather than from a vendor's pitch.

The decision factors are the ones already on this page, lined up. The upside is animal-grade: a consistent healing signal in rats, no human efficacy data, one small uncontrolled case series. The safety is unknown: no published human safety dataset, and a regulator that has flagged immunogenicity and impurity risks. The supply is unregulated: sold as a research chemical labeled not for human consumption, where what is in the vial is not guaranteed. The legal and sport status is settled and against use: not FDA-approved, not lawfully compoundable, banned in sport at all times and detectable.

Some "when not" answers are clear enough to state plainly. If you have a personal history of cancer, the theoretical concern described in the next section is reason to steer clear. If you are subject to anti-doping testing, this is a banned, detectable substance and the answer is no. If you cannot verify what is actually in the vial with a batch-specific certificate of analysis, you are dosing an unknown. And if you are pregnant or breastfeeding, there is no safety data and no reason to assume any.

If, knowing all of that, you still want to understand what real-world use looks like, the next section reports it, with the risks named and without a recommendation attached.

What people and clinics actually do with BPC-157 (and what we can't tell you)

The line that governs everything below: there is no approved clinical dose for BPC-157, and no human trial has ever tested a dose, a route, or a duration. Everything in this section is what people report doing in community forums and what some clinics publish. It is not a recommendation, it has not been validated, and it is the weakest tier of evidence on this page. We include it because pretending the real-world use doesn't exist doesn't make anyone safer. Understanding it, with the risks named, does.

What's commonly reported. Across peptide forums and clinic-published protocols, the reported pattern is unusually consistent: roughly 250 to 500 micrograms per day (250 as a starting point, titrated up; 500 the most-cited figure), by subcutaneous injection. For a specific tendon, ligament, or joint, people report injecting near the injury site; for non-localized goals, a standard subcutaneous site. Oral capsules are the other commonly discussed route, mostly for gut and digestive complaints, on the theory of direct contact with the gut lining, though whether oral even absorbs usefully is itself unsettled. Frequency is usually daily, sometimes split morning and evening; a lighter two-to-three-times-a-week pattern also circulates. Cycles are commonly described as four to six weeks on, with a two-to-four-week break, sometimes longer for slow-healing tissue.

The stack. BPC-157 is most often discussed alongside TB-500, the pairing the community calls the "Wolverine stack," injected at separate sites with TB-500 dosed less often. The exact ratio varies so widely that any precise number overstates the agreement.

What the community itself flags. The forums are not naive. The most-cited concern is not the molecule, it is the supply: BPC-157 sells as an unregulated research chemical, so experienced users treat source quality as the number-one risk, reconstitute with bacteriostatic water, and demand batch-specific third-party purity testing, a certificate of analysis, before using anything. The community also raises the theoretical cancer concern, that BPC-157 promotes blood-vessel growth in animal and cell studies, which in principle could feed an existing tumor, so anyone with a cancer history is told to steer clear; the complete absence of long-term human safety data; and scattered anecdotal side effects like lightheadedness, headache, and stomach upset. It is also banned in sport at all times.

What we can't tell you, honestly. Two cautions about the numbers above. We could not read the primary forum threads directly, because Reddit blocks automated access, so these figures come through secondary write-ups that summarize those threads. And a large share of the clinic protocols online are published by peptide-selling and wellness-marketing sites that repeat each other's numbers, so the apparent agreement is partly an echo chamber, not independent confirmation. Read the consistency as the story the market tells itself, not as evidence the dose is right or safe. We also found vendor pages citing suspiciously precise safety statistics, and we have left those out because they appear fabricated.

If you are going to explore it anyway, the harm-reduction version is straightforward: do it with a clinician who knows your history and can run baseline bloodwork, insist on a real certificate of analysis for the exact batch, and understand that you are the experiment, because the human data that would tell you whether this works, or is safe over time, does not exist. And if the honest answer for your situation is "not worth it," that is a legitimate place to land.

What the evidence implies clinically

By Dr. Sam Walters, NMD, Medical Director

BPC-157 is a familiar shape in the research literature: a molecule with a genuinely interesting laboratory record and an enthusiastic following, both running well ahead of the evidence that would tell us whether it helps, or whether it is safe, in a human body over time. The animal data are real and, within the groups that produced them, consistent, which is a fair reason to keep studying it. It is not the same as knowing what it does in people, and keeping those two apart is most of the honest read.

Two facts decide how much weight the rest can carry. The published human evidence is a single small, uncontrolled survey, and most of the promising preclinical work comes from a handful of research groups, which is exactly the setting where independent replication matters most and is least available. And this is not a benign-by-default situation: a regulator has reviewed BPC-157 and judged it may present significant safety risks, with no human safety dataset to weigh against that judgment. When the potential upside is animal-grade and the safety is genuinely unknown, caution is just arithmetic, and it is the posture I would bring to any conversation about it with a prescriber.

The honest close

For BPC-157, the evidence supports a precise and limited description: a reproducible, broadly positive body of animal research on tissue healing, essentially no human evidence beyond one small uncontrolled case series, no published human safety data, an FDA designation as a possible significant safety risk, and a standing ban in sport. The preclinical promise is real and worth following as research. The human case is not made, and the safety case is not even started. For most people, the honest read is that this is a compound to watch in the literature, not one the evidence supports using now.

We do not prescribe, and we do not recommend a dose for you. We report what is actually done in research and practice and synthesize the evidence so you can have an informed conversation with your clinician, and when the honest read is "not yet" or "probably not worth it for you," we say so.

This content is for informational purposes and is not medical advice. Consult a licensed practitioner before changing any therapeutic protocol.

We don’t prescribe. We synthesize the research so you can have an informed conversation with your prescriber. And if the honest read of the evidence is “not yet” or “probably not worth it for you” — we’ll tell you that too.